Clinical Trial

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-04-30 -> 2027-03-25 2026-06-02
minor Completion pushed: 2026-05-30 -> 2027-04-22 2026-06-02
Trial Details
NCT Number NCT06619860
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Diabetic Peripheral Neuropathic Pain
Enrollment 300 participants
Start Date 2024-10-18
Primary Completion 2027-03-25 (estimated)
Study Completion 2027-04-22 (estimated)
Updated on ClinicalTrials.gov 2026-06-01